Gaucher disease research

Gaucher disease research

Give online
to support Gaucher disease research

  • Phillippe Charles Ernest Gaucher
    Phillippe Charles Ernest Gaucher, discoverer of the disease

Professor Timothy Cox's research group is working to develop gene therapy for adults and children affected by Gaucher disease. Gaucher disease is one of the more common of the lysosomal disorders,causing enlargement of the liver and spleen, painful conditions in the bone, anaemia and a tendency to bleed.

Gaucher disease commonly affects adults as well as children; the adult form usually having started in childhood. In addition to the symptoms noted above, in very young children Gaucher disease can also affect the brain, starting off with a simple squint, but sometimes progressing to a form of epilepsy in adolescence or later childhood. 

Nobody knows why this occurs, but gene therapy seems to offer some prospect for improvement, as does enzyme therapy delivered to the brain. Research into the disease and the brain condition associated with it would be well used by the research team.

Make a donation

Make a gift now

Make a gift now to support Medicine - Cox Group Gaucher disease research by credit or debit card, or set up a direct debit:

Give online

Or, find out about other ways to give.

 

Find out more

Gaucher disease research website

This opportunity is part of

The Department of Medicine is the largest in the School of Clinical Medicine, and is comprised of 11 Divisions, each aligned to a clinical specialty within the NHS.

Related stories

Philanthropic giving is at the heart of the success of the Collegiate University, enabling us to make discoveries that change the world and to ensure that our students receive an unrivalled education. Cambridge owes its world-leading excellence in research and teaching to the generosity of its supporters. Our history is synonymous with a history of far-sighted benefaction, and the same is as true today as it has ever been.

decorative
Gift announcement
A new global health institute dedicated to advancing vaccine technology is to be established thanks to a new strategic partnership involving the University of Cambridge, along with the International Vaccine Institute (IVI), and the University of Hong Kong (HKU), and the International Vaccine Institute (IVI), thanks to philanthropic funding from the Hong Kong Jockey Club (HKJC).